AlloVir, Inc. (ALVR)
- Previous Close
0.7514 - Open
0.7630 - Bid 0.7709 x 200
- Ask 0.7835 x 200
- Day's Range
0.7400 - 0.7800 - 52 Week Range
0.5800 - 6.1200 - Volume
181,208 - Avg. Volume
475,207 - Market Cap (intraday)
89.173M - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-1.6500 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.00
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
www.allovir.com15
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Biotechnology
Industry
Recent News: ALVR
Compare To: ALVR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALVR
Valuation Measures
Market Cap
89.17M
Enterprise Value
-33.01M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.74
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
0.37
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-51.82%
Return on Equity (ttm)
-114.36%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-179.53M
Diluted EPS (ttm)
-1.6500
Balance Sheet and Cash Flow
Total Cash (mrq)
140.53M
Total Debt/Equity (mrq)
15.23
Levered Free Cash Flow (ttm)
-67.06M
Research Analysis: ALVR
Company Insights: ALVR
ALVR does not have Company Insights